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2-[18f]-Fluoro–2-deoxy-d-glucose positron emission
tomography in the evaluation of breast lesions and axillary
involvement: a comparison with mammography and
histopathological diagnosis
Oğuz HANÇERLİOĞULLARI1, Nuri ARSLAN2, Semih GÖRGÜLÜ1, Mehmet Fatih CAN1,
Hanife Aslı AYAN EKE2, Semra İNCE2, Erkan ÖZTÜRK1, Ramazan YILDIZ1, Mehmet Ali ÖZGÜVEN2

Aim: The objective of this prospective study was to evaluate the potential role of 2-[18f]-fluoro–2-deoxy-d-glucose
(FDG) positron emission tomography (PET) in the differentiation of malignant and benign breast masses and the
evaluation of axillary lymph node involvement. The secondary objective of this study was to assess the value of FDG
PET in the initial staging of patients with breast cancer.
Materials and methods: We evaluated 82 lesions in 79 consecutive patients (mean age of 54.4 ± 13.0; age range: 25–82
years) with FDG PET. While ultrasounds were performed in all cases, of the 79 patients, 72 had mammography and 58
had whole-body bone scintigraphy. All patients had a histopathological diagnosis made by 2 experienced pathologists.
Results: The sensitivity and positive predictive value of FDG PET in the differentiation of breast masses was found as
78% and 98%, respectively. The sensitivity, specificity, positive predictive value, and negative predictive value of FDG
PET in the detection of metastatic axillary invasion was 50%, 76%, 53%, and 64%, respectively. FDG PET changed the
stage of 41 patients (52%) by either downstaging [33 (41%) patients] or upstaging [8 (11%) patients], respectively.
Conclusion: Our results suggest that FDG PET has limited value in differentiating between malignant and benign
breast lesions and in the detection of metastatic axillary lymph nodes. However, FDG PET appears to have great impact
in the initial staging of patients with breast cancer and could be very helpful in the management of selected cases.
Key words: Breast cancer, FDG PET, axillary lymph node metastases, staging

Introduction
Breast cancer is the most common malignant tumor
among women all over the world and accounts for
about 30% of all cancers in women (1). It accounts
for 18% of cancer deaths in women, second only to
lung cancer for cancer-related deaths (2,3). Although
periodic physical examination and screening
mammography (MG) are very important diagnostic
methods for the early detection of breast cancer,
the specificity of these conventional methods is still

limited. Mammographic accuracy rate is low in
dense, fibrocystic, or postoperative breast tissue and
in patients who receive hormonal therapy (3). As
many as 15% of cancers are not visible on screening
MG, and only 1 out of 5 to 6 patients who underwent
biopsy for suspicious mammographic findings is
found to have breast cancer upon histopathologic
examination.
One of the most recent noninvasive methods
to overcome these problems in the diagnosis of
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breast cancer and to demonstrate axillary lymph
node metastases could be 2-[18f]-fluoro–2-deoxyd-glucose (FDG) positron emission tomography
(PET). FDG PET is not only used for imaging the
primary breast tumor, but it can be utilized in staging
patients by demonstrating regional lymph node
infiltration and distant metastasis. In this prospective
study, we aimed to evaluate the role of FDG PET in
differentiating between malignant and benign breast
masses and in the detection of axillary lymph node
metastasis.
Materials and methods
Patients
We evaluated FDG PET results of 82 lesions in 79
patients. Of 79 patients, 58 had palpable masses, and
21 patients had nonpalpable lesions with suspicious
mammographic and/or ultrasonographic findings.
Three patients had bilateral breast carcinoma. The
mean age of the patients was 54.4 ± 13.0 (range:
25–82) years. Of 79 patients, only 1 patient was male.
Of 79 patients, 40 were premenopausal, 10 were
perimenopausal, and 28 were in the postmenopausal
period. According to ultrasonography (US) and
physical examination findings, lesions greater than 1
cm were defined as palpable whereas lesions smaller
than 1 cm were defined as nonpalpable breast masses.
Of 79 patients, 73 were diagnosed with breast
cancer upon histopathological examination. Despite
benign findings upon histopathological examination,
6 patients were included in the study due to
highly suspicious findings upon US and physical
examination. Final histopathological diagnosis was
made by excisional biopsy (13 patients), incisional
biopsy (5 patients), or fine-needle aspiration
biopsy (FNAB) (61 patients). Histopathological
examinations were performed by 2 pathologists
experienced in this field. MG could not be performed
in 7 patients for technical reasons (4 patients), male
sex (1 patient), or young age (2 patients). Wholebody bone scintigraphy was performed in 58 of 79
patients.
Patients with a palpable mass upon physical
examination within the last 4 weeks or patients
with highly suspicious mammographic and/or
ultrasonographic findings such as a solid mass or

calcification were included in the study. Each patient
had a comprehensive physical breast examination
done by an experienced breast surgeon. Local ethics
committee approval and informed consent forms
from all patients were obtained.
Mammography and ultrasonography
Craniocaudal
and
mediolateral
oblique
mammographic examinations (MAMMOMAT 3
Stereo, Siemens) were performed for all patients. US
was performed using either the Acuson 128 XP/10
system + L7384 or the Philips HD I 500 system
equipped with a 50 MHz, 5–12 mm linear array
transducer. Patients were classified in 3 categories
according to mammographic and ultrasonographic
findings: suspicious, positive, and negative for
malignancy. US-guided FNAB was performed for all
suspicious lesions.
FDG PET
FDG PET images were obtained with an ECAT
EXACT PET scanner (Siemens/CTI). Following 8
h of fasting and 45 min after intravenous injection
of 10 mCi (370 MBq) 18F-FDG, sequential
transmission and emission images of the region from
the base of the scalp to the proximal femoral head
were obtained in the supine position. All FDG PET
images were interpreted by 2 experienced nuclear
medicine physicians who were aware of the clinical
information. The standardized uptake values (SUVs)
of abnormal metabolic foci were calculated.
Results
In this prospective study, we evaluated a total
of 82 lesions (58 palpable and 21 nonpalpable)
in 79 consecutive patients. Based on the final
histopathological results, 77 cases were diagnosed
as malignant and 2 cases were diagnosed as benign.
Three patients had bilateral breast carcinoma. Focal
pathologic FDG uptake was observed in 61 (77.2%)
of 79 patients. No pathologic FDG uptake was
observed in 18 (22.8%) patients. A total of 60 of 61
lesions that showed FDG uptake were malignant,
and 1 lesion was benign based on histopathological
examination. On the other hand, 1 of 18 lesions that
did not show FDG uptake was a true negative, and
17 lesions were shown to be false negatives upon
histopathological examination. FDG PET results
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in overall palpable and nonpalpable lesions as well
as sensitivity, specificity, and positive and negative
predictive values are presented in Table 1. On the
other hand, comparison of FDG PET with US and
MG in the evaluation of primary breast tumor is
summarized in Table 2.
The masses evaluated ranged in size from 0.8 to 11
cm in diameter. The benign patient group consisted
of ductal epithelial hyperplasia and granulomatous
tuberculosis mastitis. Distribution of patients by
histopathological findings is presented in Table 3.

True-positive results
Compared with histopathological results, 60 of 61
lesions that showed FDG uptake were true positives.
PET demonstrated focal areas of increased FDG
uptake corresponding to breast carcinoma in all
patients in this group (Figure 1). SUVs were 4.14
± 2.84 for the malignant lesions. FDG PET showed
multifocal breast cancer in 9 patients.
False-negative results
One out of 18 lesions that did not show FDG uptake
was a true negative, and 17 of 18 lesions were false

Table 1. Comparison of the histopathological results with FDG PET findings for overall, palpable, and nonpalpable lesions.

Histopathologic results

FDG PET results
Positive

Negative

Sv

Spc

PPV

NPV

Total

Malignant

60

17

77

Benign

1

1

2

Total

61

18

Malignant

44

13

57

Benign

1

0

1

Total

45

13

Malignant

16

4

20

Benign

0

1

1

Total

16

5

Overall lesions

77%

50%

77%

22%

79

Palpable lesions

77%

N/A

77%

22%

58

Nonpalpable lesions

80%

100%

76%

Sv: sensitivity, Spc: specificity, PPV: positive predictive value, NPV: negative predictive value, N/A: not applicable.

Table 2. Comparison of FDG PET, US, and MG in the diagnosis of breast cancer.
FDG PET

US

MG

Sensitivity

78%

83%

87%

Specificity

50%

N/A

50%

PPV

98%

97%

98%

NPV

55%

N/A

10%

PPV: positive predictive value, NPV: negative predictive value, N/A: not applicable.
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Table 3. Histopathological distribution and FDG PET results in 79 patients.
FDG PET results
True negative (1/18)

False negative (17/18)

True positive (60/61)

False positive (1/61)

Histopathological diagnosis

#

Ductal epithelial hyperplasia

1

DCIS

3

IDC

7

ILC

1

Tubular carcinoma

1

DCIS + IDC

4

DCIS + tubular carcinoma

1

IDC

33

ILC

2

DCIS

1

IDC + DCIS

12

IDC + ILC

2

Mucinous carcinoma

1

DCIS + mucinous carcinoma

2

DCIS + ILC + IDC

2

DCIS + ILC

1

IDC + micropapillary carcinoma

4

Granulomatous mastitis (tuberculosis)

1

Total

79

#: number of patients, DCIS: ductal carcinoma in situ, IDC: infiltrating ductal carcinoma, ILC: infiltrating lobular carcinoma.

SUVmax:6.6

SUVmax:9.2

A

B

C

Figure 1. A) Coronal, B) sagittal, and C) axial FDG PET images of a 42-year-old patient diagnosed with infiltrating
ductal carcinoma on fine needle aspiration biopsy. Black arrow shows focal FDG uptake corresponding to
a mass in the right breast, whereas red arrows show multiple metastatic axillary lymph nodes.
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negatives. Of the false negative lesions, 13 (76.4%)
were palpable and 4 (23.6%) were nonpalpable
tumors. Of 17 lesions, the largest pathologic tumor
reported was 4 cm in size, while the smallest tumor
was 0.2 cm in size.
True-negative results
All patients with benign breast masses were true
negative on FDG PET. Although there was high
suspicion of malignancy on US and MG in one
patient, there was no pathological FDG uptake. The
final histopathological diagnosis was ductal epithelial
hyperplasia.
False-positive results
One patient with high suspicion of malignancy on
US and MG showed focal increased FDG uptake
(SUV= 5.3) on FDG PET. We observed multiple
focally increased FDG uptakes in right paratracheal,
right infraclavicular, right interpectoral, and
right deep axillary lymph nodes. Two foci of right
superficial axillary lymph nodes were also detected,
which were thought to be metastatic. The patient
underwent axillary lymph node dissection and was
histopathologically diagnosed with granulomatous
(tuberculosis) mastitis.
Metastatic axillary involvement
Histopathological examination revealed lymph
node metastases in 28 patients. All patients were
assessed in terms of axillary lymph node involvement
with US, FDG PET, and MG. FDG PET was found
consistent with axillary invasion in 25 of 28 patients.
One patient with positive axillary uptake on FDG
PET was diagnosed with granulomatous mastitis
on histopathological examination. Most of the
metastatic lymph nodes missed on FDG PET were

less than 1 cm in size. Two metastatic lymph nodes
with infiltrating ductal carcinomas (IDC), the first of
which was 0.7 cm in size and the second of which
was 2 cm in size, were missed on FDG PET. Of all
patients, 53% (n = 42) underwent modified radical
mastectomy, 34.2% (n = 27) underwent breastconserving surgery, and neoadjuvant chemotherapy
was given to 2.7% (n = 10). Comparison of FDG PET,
MG, and US in the detection of metastatic axillary
lymph node involvement is presented in Table 4.
FDG PET changed the stage of 41 patients (52%), by
downstaging for 33 patients (41%) and upstaging for
8 patients (11%).
Discussion
Breast cancer is the second leading cause of cancerrelated deaths among women. As early detection of
breast cancer results in an obvious improvement
in survival, clinical imaging focuses on detecting
asymptomatic woman with small lesions. To date,
many types of imaging methods have been tested
for primary diagnosis, as well as for disease staging
and the evaluation of response to therapy for breast
cancer. MG has clearly been shown to be quite
sensitive for the detection of breast cancer (4).
The positive predictive value of MG has ranged
from approximately 15% to 75% (4,5). Dense
breast pattern, hormonal therapy, prior surgery or
radiotherapy, implants, and fibrocystic disease of
the breast may decrease mammographic sensitivity
(6–8). US is also known to have a low sensitivity,
with a rate of false negativity of up to 47% (4,7,9).
Moreover, breast tumors may mimic a variety of
benign parenchymal disorders, resulting in false
positive or negative screening results. Although

Table 4. Comparison of FDG PET, US, and MG in the assessment of metastatic axillary involvement.
FDG PET

US

MG

Sensitivity

50%

64%

42%

Specificity

76%

75%

81%

PPV

53%

58%

53%

NPV

64%

79%

74%

PPV: positive predictive value, NPV: negative predictive value.
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left-sided lateralization of breast cancer and axillary
involvement were reported in previous studies, we
did not investigate these data (10). Another method is
scintimammography with Tc-99m sestamibi, which
mainly accumulates in cancerous tissue as a result of
multiple factors, including mitochondrial and plasma
membrane potentials and tissue vascularization
(11). It was proven that metabolic changes in tumor
tissue generally occur before changes in anatomical
structure (12–14). Increased rate of aerobic glycolysis
can be used to detect areas of malignancy and tumor
growth with 18F-FDG molecules. Therefore, FDG
PET may have a role complementary to other imaging
modalities (12–14).
In this study, we tried to evaluate the role of
FDG PET in diagnosing primary tumor and axillary
involvement, as well as initial staging in recently
diagnosed breast cancer patients, by comparing it
with US and MG. According to our results, sensitivity,
specificity, positive predictive value (PPV), and
negative predictive value (NPV) in primary breast
cancer diagnosis are 77%, 50%, 77%, and 22%,
respectively. The sensitivity, specificity, and PPV rates
that we found were similar to those reported by Avril
et al. in their study of 144 patients (80.3%, 75.5%, and
96.6%, respectively) (14). Sensitivity rates for palpable
and nonpalpable lesions in our study were 77% and
80%, respectively. In a study of 170 patients, sensitivity
rates for tumors smaller than and greater than 1 cm
were 57% and 91%, respectively (14). The sensitivity
value obtained for the palpable lesions in this study
was higher than the value obtained for nonpalpable
lesions and/or lesions smaller than 1 cm in size, which
was consistent with previous literature data.
FDG PET’s specificity for discriminating between
benign and malignant lesions is approximately 50%,
whereas infections, inflammation, fibroadenomas,
ductal adenomas, and some granular cell tumors may
show FDG uptake and cause false positive results. In
some previous reports, the false positivity rate has
been reported as 5%–10%; this rate was only 2% in
our patient group. The cause of this may be the fact
that all patients in our group who underwent FDG
PET scanning had either breast cancer diagnosis or a
lesion highly suspicious for breast cancer.

The mean SUV for malignant lesions was 4.14 ±
2.84 in our study. It was reported in previous studies
that a SUV higher than 2.5 for tumors larger than 1
cm would indicate a 90% probability of malignancy.
Dehdashti et al. reported that the SUV for malignant
breast lesion was 4.5 ± 2.8, while the SUV was 1.05 ±
0.41 for benign ones (15). Avril et al. reported that the
SUV of malignant tumors was 2.5-fold that of benign
lesions. On the other hand, Adler et al. reported that
FDG accumulation is correlated with the pathologic
grade of the tumor (16). Slowly growing or welldifferentiated subtypes such as tubular or lobular
carcinoma and carcinoma in situ show low FDG
uptake (14,17). Lesions smaller than 1 cm, which
have lower tumor burden, may show lower FDG
uptake or may be missed as a result of limited system
resolution (17).
Previous studies conducted by Avril et al., Adler
et al., and Neiweg et al. reported false negativity
rates of 19.7%, 4%, and 9%, respectively (14,18,19).
Specifically, Adler et al. reported FDG accumulation
was correlated with the pathologic grade of the
tumor (18). In our study, the false negativity rate
for FDG PET was 21.5%; this was not statistically
different from that obtained by MG or US. FDG
PET has difficulty in detecting small-sized tumors.
In addition, FDG PET has limited use as a screening
method because of increased whole-body radiation
exposure dose, low sensitivity in some kinds of breast
tumors, and high expense (14,20).
Staging of axillary lymph nodes is known as one
of the most important prognostic factors in breast
cancer, where physical examination has sensitivity
as low as 50% (4). Computed tomography (CT),
US, and magnetic resonance imaging (MRI) do
not have enough sensitivity to demonstrate every
axillary metastasis. The sensitivity of FDG PET in
demonstrating axillary lymph nodes (50%) was
greater in comparison to that of MG (40%) in our
study group, although it has been shown to have
high false negative results in lymph nodes smaller
than 1 cm (13,21,22). FDG PET has 85% sensitivity
in detecting mediastinal and internal mammary
lymph node involvement, while the sensitivity of
CT is around 54% (23). Today, sentinel lymph node
biopsy (SLNB) is the most advanced technique for
detecting axillary lymph node metastases in primary
1219
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breast cancer. Although FDG PET cannot replace
SLNB due to its low sensitivity (31%), it may have a
complementary role in this subset of patients (24).
FDG PET has a sensitivity of 80%–97% in
determining distant metastases, while specificity
is 75%–94% (25,26). As the majority of our cases
consisted of early-stage disease, 11 patients (19%)
had distant metastases proven by FDG PET, which is
responsible for this relatively low rate.
FDG PET results also have significant effects on
treatment planning. In previous studies, it was found
that FDG PET imaging identified involved lymph
nodes or distant metastases not known before in
20% of patients, which changed clinical management
in 58% (27). Similarly, in our study, FDG PET
altered clinical management and staging, which
were determined by other methods, in 41 patients
(52%). Of those 41 patients, 33 patients (41%) were
downstaged and 8 patients (11%) were upstaged.
The results of our study are consistent with previous
studies on this issue.
FDG PET’s sensitivity is equal to that of bone
scanning, but it has a higher specificity (28). Although
Cook et al. reported that they had identified more
bone metastases using FDG PET than with scans,
there was no statistically significant difference

between either test (29). FDG PET imaging is thus
not an alternative to bone scanning, but it has a
complementary role for detecting bone metastases as
recently supported by several articles (30,31).
Although high primary tumor sensitivity rates
were reported in previous studies, it is known that
the results can be influenced by histological grade,
tumor type, tumor size, and image reconstruction.
The functional characteristics of breast tissue
may be helpful when MG and US have discrepant
or inconclusive results. Precise correlation of
PET images with those from other conventional
techniques and the introduction of new agents may
give rise to reduced biopsies of benign growths
(32,33). More sophisticated and organ-targeted newly
developed imaging systems like positron emission
mammography may help reduce the discrepancy
between radiologic and molecular imaging.
FDG PET/CT imaging may help early diagnosis
of malignant breast lesions in inconclusive MG/US
findings and may change the treatment protocols by
revealing multicentric or multifocal disease, contributing to noninvasive staging of breast cancer. As
FDG PET has a low resolution in well-differentiated
tumors and low sensitivity both in detecting in situ
cancers and axillary lymph node involvement, it cannot be used as a screening test.
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